Sirona Biochem (Seite 3096)
eröffnet am 23.06.13 12:55:10 von
neuester Beitrag 06.05.24 18:54:23 von
neuester Beitrag 06.05.24 18:54:23 von
Beiträge: 31.030
ID: 1.183.167
ID: 1.183.167
Aufrufe heute: 91
Gesamt: 5.402.421
Gesamt: 5.402.421
Aktive User: 0
ISIN: CA82967M1005 · WKN: A0RM6R · Symbol: ZSB
0,0435
EUR
-4,40 %
-0,0020 EUR
Letzter Kurs 10:08:47 Tradegate
Neuigkeiten
08.04.24 · globenewswire  |
05.04.24 · globenewswire |
28.03.24 · globenewswire |
13.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6.300,00 | +4.940,00 | |
| 1,4600 | +34,94 | |
| 1,2300 | +24,24 | |
| 2,7600 | +20,00 | |
| 0,8000 | +19,40 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 21,600 | -20,00 | |
| 1,3800 | -20,80 | |
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 |
Beitrag zu dieser Diskussion schreiben
Feedback
Sirona Biochem Announces License Agreement with Cincinnati Children's Hospital Medical Center
http://www.stockhouse.com/news/press-releases/2014/01/15/sir…
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 15, 2014) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) and Cincinnati Children's Hospital Medical Center announce the formalization of a license agreement of Cincinnati Children's patented synthetic vernix technology.
Sirona Biochem plans to create an anti-aging skin care treatment that combines their patented cell preservation glycoprotein with Cincinnati Children's technology.
Sirona will lead the development, with support from Cincinnati Children's, of the anti-aging cream incorporating the proprietary technologies of each organization. The resulting new anti-aging product will be patented with the goal of licensing the new technology to a global leader in the cosmetic and consumer packaged good marketplaces.
It is expected by both Sirona and Cincinnati Children's that new patents and applications (cosmetic and therapeutic) for this combined technology may be discovered and the collaboration is structured to support the goal of future commercial revenue from multiple sources.
"We are proud to be working in partnership with Cincinnati Children's Hospital Medical Center, a world leader in patient care and breakthrough research," said Neil Belenkie, CEO of Sirona Biochem. "Our shared goal is to create an anti-aging skin treatment that presents unparalleled efficacy and commercial opportunity for the predicted $300 billion dollar anti-aging global market."
"We are excited to formalize this agreement with Sirona Biochem and look forward to continuing to work together," said Niki Robinson, PhD, assistant vice president of Cincinnati Children's Center for Technology Commercialization.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
About Cincinnati Children's Hospital Medical Center
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S. News and World Report's 2013 Best Children's Hospitals ranking. It is ranked #1 for cancer and in the top 10 for nine of 10 pediatric specialties. Cincinnati Children's, a non-profit organization, is one of the top three recipients of pediatric research grants from the National Institutes of Health, and a research and teaching affiliate of the University of Cincinnati College of Medicine. The medical center is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at www.cincinnatichildrens.org. Connect on the Cincinnati Children's blog, via Facebook and on Twitter.
http://www.stockhouse.com/news/press-releases/2014/01/15/sir…
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 15, 2014) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) and Cincinnati Children's Hospital Medical Center announce the formalization of a license agreement of Cincinnati Children's patented synthetic vernix technology.
Sirona Biochem plans to create an anti-aging skin care treatment that combines their patented cell preservation glycoprotein with Cincinnati Children's technology.
Sirona will lead the development, with support from Cincinnati Children's, of the anti-aging cream incorporating the proprietary technologies of each organization. The resulting new anti-aging product will be patented with the goal of licensing the new technology to a global leader in the cosmetic and consumer packaged good marketplaces.
It is expected by both Sirona and Cincinnati Children's that new patents and applications (cosmetic and therapeutic) for this combined technology may be discovered and the collaboration is structured to support the goal of future commercial revenue from multiple sources.
"We are proud to be working in partnership with Cincinnati Children's Hospital Medical Center, a world leader in patient care and breakthrough research," said Neil Belenkie, CEO of Sirona Biochem. "Our shared goal is to create an anti-aging skin treatment that presents unparalleled efficacy and commercial opportunity for the predicted $300 billion dollar anti-aging global market."
"We are excited to formalize this agreement with Sirona Biochem and look forward to continuing to work together," said Niki Robinson, PhD, assistant vice president of Cincinnati Children's Center for Technology Commercialization.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
About Cincinnati Children's Hospital Medical Center
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S. News and World Report's 2013 Best Children's Hospitals ranking. It is ranked #1 for cancer and in the top 10 for nine of 10 pediatric specialties. Cincinnati Children's, a non-profit organization, is one of the top three recipients of pediatric research grants from the National Institutes of Health, and a research and teaching affiliate of the University of Cincinnati College of Medicine. The medical center is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at www.cincinnatichildrens.org. Connect on the Cincinnati Children's blog, via Facebook and on Twitter.
Sirona Biochem’s CEO to Present Shareholder Update
Vancouver, British Columbia – January 13, 2014 – Sirona Biochem Corp. (TSX-V: SBM), announces a company update to shareholders via interactive webinar.
Please join Sirona Biochem's CEO, Neil Belenkie, on January 16th at 2:30 PM, as he provides insight into the company's most recent highlights and anticipated growth plans.
The webinar format will be a presentation followed by a question / answer period.
Please register for Sirona Biochem Shareholder Update on Jan 16, 2014 2:30 PM PST at:
https://attendee.gotowebinar.com/register/434949243337402214…
After registering, you will receive a confirmation email containing information about joining the webinar.
Vancouver, British Columbia – January 13, 2014 – Sirona Biochem Corp. (TSX-V: SBM), announces a company update to shareholders via interactive webinar.
Please join Sirona Biochem's CEO, Neil Belenkie, on January 16th at 2:30 PM, as he provides insight into the company's most recent highlights and anticipated growth plans.
The webinar format will be a presentation followed by a question / answer period.
Please register for Sirona Biochem Shareholder Update on Jan 16, 2014 2:30 PM PST at:
https://attendee.gotowebinar.com/register/434949243337402214…
After registering, you will receive a confirmation email containing information about joining the webinar.
nette News - mehr nicht.
Sirona Biochem Announces Collaboration with Jean-Michel Cousteau, Fabien Cousteau, and Explore Green
http://www.stockhouse.com/news/press-releases/2014/01/13/sir…
Sirona Biochem Announces Collaboration with Jean-Michel Cousteau, Fabien Cousteau, and Explore Green
http://www.stockhouse.com/news/press-releases/2014/01/13/sir…
Antwort auf Beitrag Nr.: 46.187.905 von Jon_Schnee am 09.01.14 08:12:38The Company intends to use the proceeds from the Private Placement to support business growth through expansion of TFChem, the wholly owned subsidiary in France. Proceeds will also support phased hiring of 28 new employees in TFChem and secure operating costs of Sirona and TFChem for 2 years.
-> Nach PP sollten die Kosten für Hauptquatier (Kanada) & Labor (Frankreich) gedeckt sein. Das nehmen wir bei Wort!
Inkl. Ausbau der Mitarbeiter im Labor -> 28 Mitarbeiter.
D.h. ein massiver Ausbau im Labour von 8 Mitarbeiter auf 28!!!
Quick Facts
• Employees
• Vancouver - 6
• France - 8
-> Nach PP sollten die Kosten für Hauptquatier (Kanada) & Labor (Frankreich) gedeckt sein. Das nehmen wir bei Wort!
Inkl. Ausbau der Mitarbeiter im Labor -> 28 Mitarbeiter.
D.h. ein massiver Ausbau im Labour von 8 Mitarbeiter auf 28!!!
Quick Facts
• Employees
• Vancouver - 6
• France - 8
Antwort auf Beitrag Nr.: 46.110.831 von Jon_Schnee am 25.12.13 08:41:35Wie vermutet / befürchtet braucht Sirona erneut Geld - schon ein wenig enttäuschend. Jetzt sind wir ca. bei 250 M Stück voll verwässert - mehr sollten nicht mehr dazu kommen - sonst Reissleine!
Sirona Biochem Announces CAD$5.3 Million Private Placement
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 8, 2014) -Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB), (the "Company") announced today a non-brokered private placement of up to 33,400,000 units of the Company at a price of $0.16 CAD each (a "Unit") for gross proceeds of up to CAD$5,344,000 (the "Private Placement").
Each Unit will consist of one common share of the Company (a "Share") and one-half of one transferable share purchase warrant (a complete warrant shall be referred to as a "Warrant"). Each Warrant will entitle the holder to purchase one additional Share of the Company at any time for three years from the closing date of the Private Placement at a price of CAD$0.27 per Share.
The Company is proposing to pay a finder's fee to an agent or agents that assist in procuring the proceeds of the offering. Such Fee shall consist of a cash fee equal to no more than 8% of the total proceeds of the Private Placement placed by such finder and warrants up to 8% of the number of Units the finder sells in the Private Placement (the "Finder's Warrants"). The Finder's Warrants will be exercisable into one-half of one additional Share of the Company at a price of CAD$0.27 per Share for a period of 3 years from the closing date of the Private Placement.
The Company intends to use the proceeds from the Private Placement to support business growth through expansion of TFChem, the wholly owned subsidiary in France. Proceeds will also support phased hiring of 28 new employees in TFChem and secure operating costs of Sirona and TFChem for 2 years.
All securities to be issued under the Private Placement will be subject to a hold period in accordance with the Toronto Stock Exchange Venture ("TSXV") and/or other regulatory requirement. Closing of the Private Placement is subject to customary conditions, including TSXV acceptance.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Read more at http://www.stockhouse.com/news/press-releases/2014/01/08/sir…
Sirona Biochem Announces CAD$5.3 Million Private Placement
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 8, 2014) -Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB), (the "Company") announced today a non-brokered private placement of up to 33,400,000 units of the Company at a price of $0.16 CAD each (a "Unit") for gross proceeds of up to CAD$5,344,000 (the "Private Placement").
Each Unit will consist of one common share of the Company (a "Share") and one-half of one transferable share purchase warrant (a complete warrant shall be referred to as a "Warrant"). Each Warrant will entitle the holder to purchase one additional Share of the Company at any time for three years from the closing date of the Private Placement at a price of CAD$0.27 per Share.
The Company is proposing to pay a finder's fee to an agent or agents that assist in procuring the proceeds of the offering. Such Fee shall consist of a cash fee equal to no more than 8% of the total proceeds of the Private Placement placed by such finder and warrants up to 8% of the number of Units the finder sells in the Private Placement (the "Finder's Warrants"). The Finder's Warrants will be exercisable into one-half of one additional Share of the Company at a price of CAD$0.27 per Share for a period of 3 years from the closing date of the Private Placement.
The Company intends to use the proceeds from the Private Placement to support business growth through expansion of TFChem, the wholly owned subsidiary in France. Proceeds will also support phased hiring of 28 new employees in TFChem and secure operating costs of Sirona and TFChem for 2 years.
All securities to be issued under the Private Placement will be subject to a hold period in accordance with the Toronto Stock Exchange Venture ("TSXV") and/or other regulatory requirement. Closing of the Private Placement is subject to customary conditions, including TSXV acceptance.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Read more at http://www.stockhouse.com/news/press-releases/2014/01/08/sir…
Trading Spotlight
Offenes Haus - wer am 10 Januar in Vancouver ist:
Gerne vorbei gehen - und hier Berichten
Ich hoffe sie schlissen davor 1 oder 2 Verträge ab - den viele Anleger sind langsam ungeduldig - ich auch - damit die Open House Party wirklich eine Party wird!
Sirona Biochem Open House
Zeitpunkt Fr 10. Jan. 2014 20:00 – 23:00 (MEZ)
Wo Sirona Biochem: Sirona Biochem 605-889 W Pender St Vancouver, BC V6C 3B2
Gerne vorbei gehen - und hier Berichten
Ich hoffe sie schlissen davor 1 oder 2 Verträge ab - den viele Anleger sind langsam ungeduldig - ich auch - damit die Open House Party wirklich eine Party wird!
Sirona Biochem Open House
Zeitpunkt Fr 10. Jan. 2014 20:00 – 23:00 (MEZ)
Wo Sirona Biochem: Sirona Biochem 605-889 W Pender St Vancouver, BC V6C 3B2
Local company harnesses anti-aging properties of Antarctic fish antifreeze protein for global market
Sirona Biochem's discoveries attract attention from global cosmetics giant L'Oréal and Cincinnati Children's Hospital
http://www.biv.com/article/20131223/BIV0112/312109893/-1/BIV…...
Sirona Biochem's discoveries attract attention from global cosmetics giant L'Oréal and Cincinnati Children's Hospital
http://www.biv.com/article/20131223/BIV0112/312109893/-1/BIV…...
Antwort auf Beitrag Nr.: 46.111.473 von dottore am 25.12.13 13:45:05Ciao Dottore
Ja, Sirona ist kein easy Investment. Sind Biotech Firmen nie und schon gar keine Biotech Klitschen.
Wo würdest Du gerne investieren? Tipps sind immer willkomen
gerne hier.
oder noch besser hier posten:
http://www.wallstreet-online.de/diskussion/1186055-neustebei…
Antwort wäre Klasse
Ja, Sirona ist kein easy Investment. Sind Biotech Firmen nie und schon gar keine Biotech Klitschen.
Wo würdest Du gerne investieren? Tipps sind immer willkomen
gerne hier.
oder noch besser hier posten:
http://www.wallstreet-online.de/diskussion/1186055-neustebei…
Antwort wäre Klasse
sehr schwer einzuschätzen. Gleichzeitig gibt es eine Reihe anderer Investmöglichkeiten, die mir mehr bei weniger Aufwand versprechen.
Ich glAUBE NICHT; DASS ICH HIER EINSTEIGEN WERDE:
fINDE GUT; DASS DU selbst distanziert schreibst und nicht blind puschst.
Finde die kritischen Beiträge von DJ etwas zu persönlich angreifend.
Viel Glück hier, besser: Investier wo anders!
Ich glAUBE NICHT; DASS ICH HIER EINSTEIGEN WERDE:
fINDE GUT; DASS DU selbst distanziert schreibst und nicht blind puschst.
Finde die kritischen Beiträge von DJ etwas zu persönlich angreifend.
Viel Glück hier, besser: Investier wo anders!
Antwort auf Beitrag Nr.: 46.110.831 von Jon_Schnee am 25.12.13 08:41:35Grösste Fanatasie derzeit sicher bei Skin Lightening
http://www.sironabiochem.com/wp-content/uploads/2013/05/SBM-…
2 ähnlihce Wirkstoffe:
TFC-849: Gib's ein LOI ->
Sirona Biochem Signs Letter of Intent with Obagi Medical Products
http://www.sironabiochem.com/sirona-biochem-signs-letter-of-…
Obagi wurde von Valenat übernommen:
Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
Valeant Pharmaceuticals International, Inc. (VRX) -NYSE
Kurs: 113 USD / Market Cap: 37.74B / Revenue (ttm): 4.69B
VALEANT ist also kein kleines Unternehmen.
-> hier hoffe ich bei Unterschrift auf eine erste Milestone Zahlung.
Wenn das nicht passiert -> neue Verwässerung!!!
and TFC-723: ??? Hoffe auf einen anderen Major
http://www.sironabiochem.com/wp-content/uploads/2013/05/SBM-…
2 ähnlihce Wirkstoffe:
TFC-849: Gib's ein LOI ->
Sirona Biochem Signs Letter of Intent with Obagi Medical Products
http://www.sironabiochem.com/sirona-biochem-signs-letter-of-…
Obagi wurde von Valenat übernommen:
Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
Valeant Pharmaceuticals International, Inc. (VRX) -NYSE
Kurs: 113 USD / Market Cap: 37.74B / Revenue (ttm): 4.69B
VALEANT ist also kein kleines Unternehmen.
-> hier hoffe ich bei Unterschrift auf eine erste Milestone Zahlung.
Wenn das nicht passiert -> neue Verwässerung!!!
and TFC-723: ??? Hoffe auf einen anderen Major
Durchsuchen
